PMID-36482258 – NMN Dose-Dependent Safety RCT in Middle-Aged Adults
Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Bhatt S, Chew DJ, Bhatt DL. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43.
Quick Reference
| Property | Value |
|---|---|
| PMID | 36482258 |
| DOI | 10.1007/s11357-022-00705-1 |
| Year | 2023 |
| Journal | GeroScience |
| Study Type | RCT (multicenter) |
| Evidence Level | II |
| Sample | 80 healthy middle-aged adults, NMN 300/600/900 mg/day |
| Peptide(s) Studied | NAD+ |
Key Findings
- All NMN doses (300, 600, and 900 mg/day) were well-tolerated with safety profiles comparable to placebo
- Dose-dependent increases in blood NAD+ levels confirmed target engagement across all dose groups
- Improved walking endurance on the 6-minute walk test, suggesting functional benefit from NAD+ elevation
Study Design
Randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent trial. Eighty healthy middle-aged adults were randomized to NMN 300 mg/day, 600 mg/day, 900 mg/day, or placebo. Primary endpoints included safety and tolerability; secondary endpoints included blood NAD+ concentrations and physical performance measures including the 6-minute walk test.
Limitations
- Relatively short study duration for assessing long-term safety and aging outcomes
- Healthy volunteer population may not reflect effects in metabolically compromised individuals
Clinical Relevance
As the largest NMN dose-ranging safety trial, this study provides critical dose-response data supporting NMN supplementation at multiple dose levels and confirms that NAD+ elevation translates to measurable functional improvements in middle-aged adults.
Related
#research #RCT #evidence-level-II